Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Subscribe To Our Newsletter & Stay Updated
